Two KRAS-targeted strategies are starting to reshape treatment for metastatic pancreatic cancer after decades of limited progress with chemotherapy.

Safety, pharmacokinetics (PK), and cost-effectiveness of upfront genotyping of DPYD in fluoropyrimidine therapy. CpG island methylation in PTEN, MGMT, and E/H cadherin promoters, mutations of K-ras ...

Similarities in treatment (Tx) patterns and clinical outcomes (CO) in patients (pts) with metastatic colorectal cancer (mCRC) initially treated with FOLFOX/BV or FOLFIRI/BV: Results from ARIES, a ...

Mutations of KRAS have long been targets of interest for the development of new cancer therapies, but structural changes caused by these mutations have made it particularly difficult to target and ...

The experimental drug daraxonrasib, which doubled survival time in patients with advanced pancreatic cancer, may also prove ...